Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.58 |
| ▸ | JAK1 | P23458 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | STS | P08842 | 1/20 | 0.53 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.52 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.48 |
| ▸ | PTPRB | P23467 | 1/20 | 0.48 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | YAP1 | P46937 | 1/20 | 0.47 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL803627 | 0.89 | KDM4E (0.57) | JAK2JAK1KDM4EPKMSTS | |
| SCHEMBL7588639 | 0.85 | KDM4E (0.53) | JAK2JAK1KDM4EPKMSTS | |
| SCHEMBL30812219 | 0.85 | JAK2 (0.55) | JAK2JAK1KDM4EPKMSTS | |
| SCHEMBL784816 | 0.85 | ACHE (0.53) | ACHENPC1 | |
| SCHEMBL31697910 | 0.85 | SMN1; SMN2 (0.52) | JAK2JAK1KDM4EPKMSTS | |
| SCHEMBL27140943 | 0.85 | SMN1; SMN2 (0.52) | JAK2JAK1KDM4EPKMSTS | |
| SCHEMBL28978021 | 0.83 | KDM4E (0.58) | JAK2JAK1KDM4EPKMSTS | |
| SCHEMBL19867107 | 0.83 | KDM4E (0.58) | JAK2JAK1KDM4EPKMSTS | |
| SCHEMBL31522162 | 0.83 | GPR119 (0.55) | JAK2JAK1KDM4EPKMSTS | |
| SCHEMBL26668523 | 0.83 | GPR119 (0.56) | JAK2JAK1KDM4EPKMGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4613748-A1 | IRAK4 DEGRADATION AGENT AND USE THEREOF | Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. (CN) | 2025-09-10 | — | — | EP | disclosed |
| US-20240368194-A1 | IRAK4 DEGRADATION AGENT, AND PREPARATION METHOD THEREFOR AND USE THEREOF | LEADINGTAC PHARMACEUTICAL (SHAOXING) CO., LTD. (CN) | 2024-11-07 | — | — | US | disclosed |
| EP-4393922-A1 | IRAK4 DEGRADATION AGENT, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Leadingtac Pharmaceutical Co. Ltd. (CN) | 2024-07-03 | — | — | EP | disclosed |
| US-20230242541-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-08-03 | — | — | US | disclosed |
| CN-116261458-A | Novel PLK1 degradation inducing compounds | 厄普特拉株式会社 | 2023-06-13 | — | — | CN | disclosed |
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | disclosed |
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | disclosed |
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | disclosed |
| WO-2012038081-A1 | SUBSTITUTED BENZAMIDE COMPOUNDS | Grünenthal GmbH (DE) | 2012-03-29 | — | — | WO | disclosed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368194-A1 | IRAK4 DEGRADATION AGENT, AND PREPARATION METHOD THEREFOR AND USE THEREOF | IRAK4, IRAK2, IRAK1 | JAK2 657/4885JAK1 304/4885KDM4E 184/4885 |
| US-20230242541-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | PLK1, BUB1B, BUB1 | JAK2 3424/4885JAK1 3029/4885KDM4E 1918/4885 |
| US-20120071461-A1 | Substituted Benzamide Compounds | BDKRB1, BDKRB2, HRH2 | JAK2 1298/4885JAK1 1517/4885KDM4E 2727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.